Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of NK105 Plus Carboplatin in Japanese Patients With Advanced Solid Cancers
jRCT2080223202Phase 1
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- May 2016
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK105 in malignant solid tumor, sponsored by Nippon Kayaku Co., Ltd. Primary endpoint: Safety and tolerability of NK105 when co-administered with carboplatin.
02
Drugs
NK105
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on jRCT2080223202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223202.